Zolbetuximab Plus CAPOX Beneficial for Advanced mG/GEJ Adenocarcinoma
FRIDAY, Sept. 1, 2023 (HealthDay News) -- For patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma, zolbetuximab, a monoclonal antibody that targets claudin-18 isoform 2 (CLDN18.2), plus capecitabine and oxaliplatin (CAPOX) prolongs progression-free survival (PFS) and overall survival (OS) versus placebo plus CAPOX, according to a study published online July 31 in Nature Medicine.
Manish A. Shah, M.D., from Weill Cornell Medical College in New York City, and colleagues conducted a phase 3 study to examine zolbetuximab plus CAPOX as first-line treatment for CLDN18.2-positive, HER2-negative, locally advanced unresectable or mG/GEJ adenocarcinoma in 507 patients randomly assigned to zolbetuximab plus CAPOX or placebo plus CAPOX in a 1:1 ratio.
The researchers found that PFS, the primary end point, was significantly prolonged for patients randomly assigned to receive zolbetuximab versus placebo (median, 8.21 versus 6.90 months; hazard ratio [HR], 0.687), as was OS, the key secondary end point (median, 14.39 versus 12.16 months; HR, 0.771). Treatment-emergent adverse events of grade 3 or higher occurred in 72.8 and 69.9 percent of those receiving zolbetuximab and placebo, respectively.
"We now have evidence from two large trials showing that the addition of zolbetuximab provides a meaningful survival benefit for patients with CLDN18.2-positive gastric cancers," Shah said in a statement. "If zolbetuximab is approved, patients will be able to decide with their physicians whether zolbetuximab plus CAPOX or mFOLFOX [folinic acid plus 5-fluorouracil and oxaliplatin] is the right regimen for them."
Several authors disclosed ties to the biopharmaceutical industry, including Astellas Pharma Inc., which funded the study and manufactures zolbetuximab.
Related Posts
Metabolic Health Tied to Risk for Obesity-Related Cancers
THURSDAY, Feb. 23, 2023 (HealthDay News) -- Metabolic obesity phenotype is...
Most Dog Breeds Are Highly Inbred — and Unhealthy
TUESDAY, Dec. 7, 2021 (HealthDay News) -- Traits particular to certain dog...
Los estadounidenses podrían tener más probabilidades de sufrir Parkinson de lo que se pensaba
JUEVES, 15 de diciembre de 2022 (HealthDay News) -- La enfermedad de Parkinson...
Increasing Daily Step Counts Tied to Improved Heart Failure Outcomes
FRIDAY, July 28, 2023 (HealthDay News) -- Increasing step counts are...